Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lansoprazole + amoxicillin + metronidazole
- Development stage
- Phase 4
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A triple therapy combination used for the treatment and eradication of Helicobacter pylori infection, particularly in cases of duodenal ulcers. This regimen combines lansoprazole (a proton pump inhibitor that reduces gastric acid secretion) with two antibiotics (amoxicillin and metronidazole) to effectively eliminate H. pylori bacteria. This combination is particularly valuable in areas with high prevalence of clarithromycin resistance.
02
Targets
NeuraminidasePBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on lansoprazole + amoxicillin + metronidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lansoprazole + amoxicillin + metronidazole.